<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Adv Biomed Res</journal-id><journal-id journal-id-type="iso-abbrev">Adv Biomed Res</journal-id><journal-id journal-id-type="publisher-id">ABR</journal-id><journal-title-group><journal-title>Advanced Biomedical Research</journal-title></journal-title-group><issn pub-type="epub">2277-9175</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23326789</article-id><article-id pub-id-type="pmc">3544099</article-id><article-id pub-id-type="publisher-id">ABR-1-58</article-id><article-id pub-id-type="doi">10.4103/2277-9175.100176</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Comparison of the administration of progesterone versus progesterone and vitamin D in improvement of outcomes in patients with traumatic brain injury: A randomized clinical trial with placebo group</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Aminmansour</surname><given-names>Bahram</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Nikbakht</surname><given-names>Hossein</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Ghorbani</surname><given-names>Abbas</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib><contrib contrib-type="author"><name><surname>Rezvani</surname><given-names>Majid</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Rahmani</surname><given-names>Paiman</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Torkashvand</surname><given-names>Mostaffa</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Nourian</surname><given-names>Mohammadamin</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Moradi</surname><given-names>Mehran</given-names></name><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff id="aff1">Department of Neurosurgery, Isfahan University Of Medical Sciences, Isfahan, Iran</aff><aff id="aff2"><label>1</label>Department of Neurology, Al-zahra Hospital, Isfahan University Of Medical Sciences, Isfahan, Iran</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Hossein Nikbakht, Neurosurgery Department, Al-Zahra Hospital, Isfahan University Of Medical Sciences, Isfahan, Iran. E-mail: <email xlink:href="nikbakht67@yahoo.com">nikbakht67@yahoo.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>28</day><month>8</month><year>2012</year></pub-date><volume>1</volume><elocation-id>58</elocation-id><history><date date-type="received"><day>27</day><month>4</month><year>2012</year></date><date date-type="accepted"><day>08</day><month>7</month><year>2012</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2012 Aminmansour</copyright-statement><copyright-year>2012</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><sec id="st1"><title>Background:</title><p>Due to the heterogeneity of traumatic brain injury (TBI), many of single treatments have not been successful in prevention and cure of these kinds of injuries. The neuroprotective effect of progesterone drug on severe brain injuries has been identified, and recently, the neuroprotective effect of vitamin D has also been studied as the combination of these two drugs has shown better effects on animal samples in some studies. This study was conducted to examine the effect of vitamin D and progesterone on brain injury treatment after brain trauma.</p></sec><sec id="st2"><title>Materials and Methods:</title><p>This study was performed on patients with severe brain trauma (Glasgow Coma Scale (GCS) &#x02264; 8) from April to September, 2011. The patients were divided to 3 groups (placebo, progesterone, progesterone-vitamin D), each with 20 people. Upon the patients&#x02019; admission, their GCS and demographic information were recorded. After 3 months, they were reassessed, and their GCS and GOS (Glasgow outcome scale) were recorded. The collected data were analyzed using SPSS 18 software (SPSS Inc., Chicago IL, USA).</p></sec><sec id="st3"><title>Results:</title><p>Before intervention, GCS mean of the placebo, progesterone, and progesterone-vitamin D groups were 6.3 &#x000b1; 0.88, 6.31 &#x000b1; 0.87, and 6 &#x000b1; 0.88, respectively. They increased to 9.16 &#x000b1; 1.11, 10.25 &#x000b1; 1.34, and 11.27 &#x000b1; 2.27, respectively 3 months after intervention. There was a significant difference among GCS means of the 3 groups (<italic>P-value</italic> = <italic>0.001</italic>). GOS was classified to 2 main categories of favorable and unfavorable recovery, of which, favorable recovery in placebo, progesterone, and progesterone-vitamin D was 25%, 45%, and 60%, respectively which showed a statistical significant difference among the groups (<italic>P-value</italic> = <italic>0.03</italic>).</p></sec><sec id="st4"><title>Conclusion:</title><p>The results showed that recovery rate in patients with severe brain trauma in the group receiving progesterone and vitamin D together was significantly higher than that of progesterone group, which was in turn higher than that of placebo group.</p></sec></abstract><kwd-group><kwd>Progesterone</kwd><kwd>severe brain trauma</kwd><kwd>vitamin D</kwd></kwd-group></article-meta></front><body><sec id="sec1-1"><title>INTRODUCTION</title><p>Injuries arising from brain trauma are among the causes of death and severe disabilities. Management of brain traumatic injuries includes prevention of neurological complications, intracranial pressure monitoring, and surgical procedures. Finding drugs which are effectively neuroprotective is of special importance for prevention of secondary brain injury after trauma. Attempts have been made, for more than 30 years, to discover an effective and harmless compound which acts as a neuroprotective in brain injuries.[<xref ref-type="bibr" rid="ref1">1</xref>] During last two decades, all the clinical trials phase II and III for the moderate and severe traumatic brain injuries failed.[<xref ref-type="bibr" rid="ref1">1</xref>] So far, 130 drugs have been effective on brain injury in animal samples,[<xref ref-type="bibr" rid="ref2">2</xref>] although they were not effective in clinical trials and do not have any neuroprotective effects.[<xref ref-type="bibr" rid="ref2">2</xref><xref ref-type="bibr" rid="ref3">3</xref>] One reason is the complexity and diversity of the mechanisms related to different types of TBI, which are not cured by a single drug and cover only one or few receptors.[<xref ref-type="bibr" rid="ref1">1</xref><xref ref-type="bibr" rid="ref4">4</xref>] Among the studied drugs, progesterone (PROG) has been identified as an effective and safe compound, which is a neuroactive steroidal hormone having neurosteroidal activity in central nervous system.[<xref ref-type="bibr" rid="ref5">5</xref>&#x02013;<xref ref-type="bibr" rid="ref7">7</xref>] In traumatic brain injuries and strokes, this hormone causes blood-brain barrier protection, cerebral edema reduction, inflammatory response, necrosis and apoptosis and stimulation of myelin formation, free radicals reduction, and neuronal loss reduction.[<xref ref-type="bibr" rid="ref8">8</xref>&#x02013;<xref ref-type="bibr" rid="ref11">11</xref>]</p><p>Similar to progesterone, vitamin D (VDH) is a neurosteroid acting like a PROG in neuroprotective process.[<xref ref-type="bibr" rid="ref1">1</xref>] It causes the expression of more than 1000 genes that consequently results in activation of many pathways in CNS (central nervous system).[<xref ref-type="bibr" rid="ref12">12</xref>] Therefore, VHD in combination with PROG may cure the patients. Recent studies have shown that vitamin D deficiency may intensify traumatic brain injury and reduce the effects of other therapies for TBI. This problem becomes important with respect to the elderly, since, of whom more than 50% suffer from vitamin D deficiency.[<xref ref-type="bibr" rid="ref13">13</xref>] There are evidences that 30 to 50% of American people suffer from vitamin D deficiency, so that, all the patients with TBI of any age are at risk of unfavorable outcome.[<xref ref-type="bibr" rid="ref13">13</xref>] Given that the studies examining the effect of the combined PROG and VDH on neural recovery after TBI were most conducted on animals, the present study assessed the effect of these two compounds on outcome improvement in patients with TBI.</p></sec><sec sec-type="materials|methods" id="sec1-2"><title>MATERIALS AND METHODS</title><p>This clinical trial was performed in Alzahra Hospital, Isfahan, Iran, in 2010.</p><sec id="sec2-1"><title>Inclusion criteria of the study</title><p>
<list list-type="bullet"><list-item><p>Patients with brain trauma and diffuse axonal injury</p></list-item><list-item><p>Patients with GCS &#x0003c; 8</p></list-item></list>
</p></sec><sec id="sec2-2"><title>Exclusion criteria of the study</title><p>
<list list-type="bullet"><list-item><p>Patient's legal representative does not consent to patient's participation in the study.</p></list-item></list>
</p></sec><sec id="sec2-3"><title>Sampling method</title><p>Simple random</p></sec><sec id="sec2-4"><title>Number of samples</title><p>20 patients were selected in each group through simple random sampling.</p><p>The patients were randomly divided into 3 groups, each with 20 people. Within 8 hours after traumatic injury, the patients in the first group were injected 1 mg/kg of progesterone intramuscularly every 12 hours for 5 days, and the patients in the second group were injected 1 mg/kg of progesterone intramuscularly every 12 hours for 5 days and also 5 &#x003bc;g/kg vitamin D once-a-day for 5 days. The third group as the control group received placebo (Both placebos were injected intravenously). Patients&#x02019; level of consciousness was periodically controlled based on Glasgow Coma Scale (GCS) during hospitalization and 1 month after treatment, and Glasgow Outcome Scale (GOS) was controlled after 3 months. GOS criteria were defined as follows:</p><p>5 = Good recovery: Normal or near normal recovery</p><p>4 = Moderate disability: Disable but independent</p><p>3 = Severe disability: Dependent with physical / psychological disabilities</p><p>2 = Persistent vegetative state</p><p>1 = Dead</p><p>Finally, these criteria were divided into 2 categories of &#x0201c;favorable&#x0201d; (good recovery and moderate disability) and &#x0201c;unfavorable&#x0201d; (the other 3 criteria).[<xref ref-type="bibr" rid="ref5">5</xref>] Analysis of the data was done using SPSS 18 software. Qualitative and quantitative data of the groups were compared using Chi square and One-way ANOVA tests, respectively. Comparison of GCS and GOS variations, before and after intervention and among the 3 groups, was done using repeated measurement ANOVA.</p></sec></sec><sec sec-type="results" id="sec1-3"><title>RESULTS</title><p>This study was carried out in Trauma Center of Alzahra Hospital, Isfahan, Iran, from April to September, 2011. 3 groups of 20 patients were studied and followed up over 3 months.[<xref ref-type="bibr" rid="ref5">5</xref>] Demographic specifications showed no significant difference among the 3 groups, i.e., the patients were matched in this regard [<xref ref-type="table" rid="T1">Table 1</xref>].</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Clinical and demographic characteristics between 3 groups</p></caption><graphic xlink:href="ABR-1-58-g001"/></table-wrap><p>Before intervention, GCS mean of the placebo, progesterone, and progesterone-vitamin D groups comprised 6.3 &#x000b1; 0.88, 6.31 &#x000b1; 0.87, and 6 &#x000b1; 0.88, respectively, which 3 months after intervention, increased to 9.16 &#x000b1; 1.11, 10.25 &#x000b1; 1.34, and 11.27 &#x000b1; 2.27, respectively. There was a significant difference among GCS means of the 3 groups (<italic>P</italic>-value = 0.001) [<xref ref-type="fig" rid="F1">Figure 1</xref>].</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Comparison of GCS at administration and 3 month later between 3 groups</p></caption><graphic xlink:href="ABR-1-58-g002"/></fig><p>GOS values of the patients, 3 months after trauma, are shown in <xref ref-type="table" rid="T2">Table 2</xref>. Recovery rate in the group receiving progesterone and vitamin D together was higher than that of other groups; consequently, mortality rate in this group was less than that of others (<italic>P</italic>-value = 0.03).</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Comparison of Glasgow outcome Scale scores between the progesterone, progesterone&#x02013;Vitamin D, and placebo groups at 3 months later</p></caption><graphic xlink:href="ABR-1-58-g003"/></table-wrap><p>Favorable responses in placebo, progesterone, and progesterone-vitamin D comprised 25%, 45%, and 60%, respectively which showed a statistical significant difference among the groups (<italic>P</italic>-value = 0.03) [<xref ref-type="fig" rid="F2">Figure 2</xref>].</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>Comparison of dichotomized Glasgow Outcome scale score for patients receiving placebo or progesterone or progesterone and vitamin D after 3 month</p></caption><graphic xlink:href="ABR-1-58-g004"/></fig><p>In this study, mean mortality rate was 23.3% (14 patients) as the mortality rate in the placebo, progesterone-vitamin D, and progesterone groups was 40% (8 patients), 10% (2 patients), and 20% (4 patients), respectively. These rates showed a significant difference among groups (<italic>P</italic>-value = 0.000).</p></sec><sec sec-type="discussion" id="sec1-4"><title>DISCUSSION</title><p>Numerous studies have been done on TBI treatment. However, most of them were conducted under <italic>in vitro</italic> and <italic>in vivo</italic> conditions. There have been also few studies on TBI treatment with combined progesterone and vitamin D, especially on human samples. In this study, progesterone and progesterone-vitamin D were found to improve the patients&#x02019; outcome as the recovery rate in the group with combination therapy was significantly more than that in other groups. Moreover, GCS variations and mortality rate in the group with combination therapy were significantly less than those in other groups. Favorable outcome of the group with combination therapy was significantly more than those in other groups. A similar study performed under <italic>in vitro</italic> condition[<xref ref-type="bibr" rid="ref1">1</xref>] showed that low dose PROG (0.01, 0.1, and 1.5 &#x003bc;mol/l) did not reduce glutamate-induced cell death, whereas with higher doses (10, 24, 40, and 80 &#x003bc;mol/l), PROG significantly reduced LDH and MTT as the optimum dose of PROG was reported as 20 &#x003bc;mol/l. Furthermore, therapeutic responses to vitamin D were found to have a U-shaped pattern as the most favorable response was found in low doses (0.001 - 0.5 &#x003bc;mol/l), and the least neuroprotective effect was found in higher doses (1 - 10 &#x003bc;mol/l).[<xref ref-type="bibr" rid="ref1">1</xref>] In the above study, the combination of vitamin D (0.1 &#x003bc;mol/l) and PROG (20 &#x003bc;mol/l) showed no significant preventive effect than the other group, and this was contrary to the U-shaped pattern of response to vitamin D; however, the combined PROG (20 &#x003bc;mol/l) and VDH (20 &#x003bc;mol/l) significantly reduced cell death and was more effective than any of the drugs alone.</p><p>Another study on the effect of progesterone alone showed more favorable outcome and much less mortality rate for the patients in progesterone group.[<xref ref-type="bibr" rid="ref5">5</xref>]</p><p>The effect of progesterone on &#x003c3;1 receptor acts as a competitive inhibitor and may reduce N-methyl-D-aspartate (NMDA) glutamate signaling.[<xref ref-type="bibr" rid="ref14">14</xref><xref ref-type="bibr" rid="ref15">15</xref>] Moreover, PROG affects nicotinic acetylcholine receptor (nAChR)[<xref ref-type="bibr" rid="ref16">16</xref>] and stimulates gamma-aminobutyric acid (GABA) as the most important inhibition transmitter in brain. All the above 3 mechanisms are responsible for the positive neuroprotective effects of PROG as they inhibit the excitotoxic responses in injuries.[<xref ref-type="bibr" rid="ref13">13</xref>]</p><p>Vitamin D belongs to the secosteroid class, which directly causes the expression of more than 100 genes.[<xref ref-type="bibr" rid="ref17">17</xref>] This neuroactive steroid can be dispersed in CNS since it is the final activator of enzymes and has an intracellular receptor. The primary effects of vitamin D are the inhibition of cell proliferation and stimulation of cellular differentiation, especially in immune system.[<xref ref-type="bibr" rid="ref18">18</xref><xref ref-type="bibr" rid="ref19">19</xref>] It has been found that vitamin D deviates all the dimensions of immune performance, which is near the immune response type 2 and generally is anti-inflammatory and regulatory.[<xref ref-type="bibr" rid="ref13">13</xref>] Similar to progesterone, vitamin D reduces the pro-inflammatory level of TH1 cytokines such as IL6, IL12, IL1B, and TNF&#x003b1;.[<xref ref-type="bibr" rid="ref20">20</xref>] Furthermore, vitamin D maintains the intracellular surface of calcium through following ways: 1. Maintenance of PTH at an appropriate level, 2. Adjustment of L-type voltage-sensitive calcium channels, and 3. Control of intracellular Ca<sup>2+</sup> buffering.</p><p>The progesterone activity through GABAergic system to inhibit extracellular activity and the performance of vitamin D to increase intracellular Ca<sup>2+</sup>-binding proteins together affect the calcium metabolism through sub-pathways.</p><p>Other reasons for the use of combined PROG and vitamin D in TBI treatment are as follows:</p><p>
<list list-type="bullet"><list-item><p>Reduction of the effects of glutamate release and calcium inflex</p></list-item><list-item><p>Protection against toxic effects of heme breakdown products</p></list-item><list-item><p>Enhancement of free radical scavenging</p></list-item><list-item><p>Modulation of the renin-angiotensin system</p></list-item><list-item><p>Protection of the axonal and cytoskeleton infrastructure</p></list-item></list>
</p></sec><sec sec-type="conclusion" id="sec1-5"><title>CONCLUSION</title><p>As mentioned before, vitamin D and progesterone are pleiotropic hormones with a lot of common pathways, which consequently reduce the CNS injury and increase recovery rate of nervous system after TBI. Many studies performed on mice and humans have reported significant favorable outcome after TBI.[<xref ref-type="bibr" rid="ref21">21</xref>&#x02013;<xref ref-type="bibr" rid="ref23">23</xref>] Recently, progesterone has been found to reduce inflammatory response and oxidative stress.[<xref ref-type="bibr" rid="ref24">24</xref><xref ref-type="bibr" rid="ref25">25</xref>] Moreover, progesterone activates the protective pathways and increases the expression of genes and proteins related to neuroprotection after TBI.[<xref ref-type="bibr" rid="ref13">13</xref>] There are also reports about the neuroprotective effect of vitamin D under <italic>in vitro</italic> and <italic>in vivo</italic> conditions and cortical infarcts.[<xref ref-type="bibr" rid="ref26">26</xref>] Furthermore, studies have shown that vitamin D deficiency disrupts the processes associated with CNS health such as mitosis, mitogenesis, neurite outgrowth, possibly adult neurogenesis in hippocampal cells, and mitochondria function.[<xref ref-type="bibr" rid="ref27">27</xref>]</p><p>Regarding the foregoing, the use of combined PROG and vitamin D is reasonable in that vitamin D in combination with PROG improves repair mechanisms of CNS considering their common pathways, and also compensates other mechanisms, which are not performed by PROG. This reduces the heterogeneity of TBI and the probable failure of a single treatment.</p></sec></body><back><fn-group><fn fn-type="supported-by"><p><bold>Source of Support:</bold> Nil</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> None declared</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atif</surname><given-names>F</given-names></name><name><surname>Sayeed</surname><given-names>I</given-names></name><name><surname>Ishrat</surname><given-names>T</given-names></name><name><surname>Stein</surname><given-names>DG</given-names></name></person-group><article-title>Progesterone with Vitamin D affords better neuroprotectionagainst excitotoxicity in cultured cortical neurons than progesterone alone</article-title><source>Mol Med</source><year>2009</year><volume>15</volume><fpage>328</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">19603099</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Margulies</surname><given-names>S</given-names></name><name><surname>Hicks</surname><given-names>R</given-names></name></person-group><article-title>Combination Therapies for Traumatic Brain Injury Workshop</article-title><year>2008</year><publisher-loc>Rockville, MD</publisher-loc><comment>Participants</comment></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>I</given-names></name><name><surname>Schierhout</surname><given-names>G</given-names></name><name><surname>Alderson</surname><given-names>P</given-names></name></person-group><article-title>Absence of evidence for the effectiveness of five interventions routinely used in the intensive care management of severe head injury: A systematic review</article-title><source>Neurol Neurosurg Psychiatry</source><year>1998</year><volume>65</volume><fpage>729</fpage><lpage>33</lpage></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muzelaar</surname><given-names>JP</given-names></name><name><surname>Mararon</surname><given-names>A</given-names></name><name><surname>Young</surname><given-names>HF</given-names></name></person-group><article-title>Improving the outcome of severe head injury with oxygen radical scavenger polyethylene glycol-conjugated superoxide dismutase: A phase trial</article-title><source>J Neurosury</source><year>1993</year><volume>78</volume><fpage>375</fpage><lpage>82</lpage></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>G</given-names></name><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name></person-group><article-title>Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: A randomized controlled trial</article-title><source>Crit Care</source><year>2008</year><volume>12</volume><fpage>R61</fpage><pub-id pub-id-type="pmid">18447940</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Djebaili</surname><given-names>M</given-names></name><name><surname>Guo</surname><given-names>Q</given-names></name><name><surname>Pettus</surname><given-names>EH</given-names></name><name><surname>Hoffman</surname><given-names>SW</given-names></name><name><surname>Stein</surname><given-names>DG</given-names></name></person-group><article-title>The neurosteroids progesterone and allopregnanolone reduce cell death, gliosis, and functional deficits after traumatic brain injury in rats</article-title><source>J Neurotrauma</source><year>2005</year><volume>22</volume><fpage>106</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">15665606</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roof</surname><given-names>RL</given-names></name><name><surname>Hall</surname><given-names>ED</given-names></name></person-group><article-title>Gender differences in acute CNS trauma and stroke: Neuroprotective effects of estrogen and progesterone</article-title><source>J Neurotrauma</source><year>2000</year><volume>17</volume><fpage>367</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">10833057</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>DG</given-names></name></person-group><article-title>Progesterone exerts neuroprotective effects after brain injury</article-title><source>Brain Res Rev</source><year>2008</year><volume>57</volume><fpage>386</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">17826842</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roof</surname><given-names>RL</given-names></name><name><surname>Hoffman</surname><given-names>SW</given-names></name><name><surname>Stein</surname><given-names>DG</given-names></name></person-group><article-title>Progesterone protects against lipid peroxidation following traumatic brain injury in rats</article-title><source>Mol Chem Neuropathol</source><year>1997</year><volume>31</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">9271001</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roof</surname><given-names>RL</given-names></name><name><surname>Duvdevani</surname><given-names>R</given-names></name><name><surname>Stein</surname><given-names>DG</given-names></name></person-group><article-title>Progesterone treatment attenuates brain edema following contusion injury in male and female rats</article-title><source>Restor Neurol Neurosci</source><year>1992</year><volume>4</volume><fpage>425</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">21551677</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ransohoff</surname><given-names>RM</given-names></name><name><surname>Tani</surname><given-names>M</given-names></name></person-group><article-title>Do chemokines mediate leukocyte recruitment in post-traumatic CNS inflammation?</article-title><source>Trends Neurosci</source><year>1998</year><volume>21</volume><fpage>154</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">9554725</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eelen</surname><given-names>G</given-names></name><name><surname>Verlinden</surname><given-names>L</given-names></name><name><surname>van Camp</surname><given-names>M</given-names></name><name><surname>van Hummelen</surname><given-names>P</given-names></name><name><surname>Marchal</surname><given-names>K</given-names></name><name><surname>de Moor</surname><given-names>B</given-names></name><etal/></person-group><article-title>The effects of 1alpha, 25- dihydroxyvitamin D3 on the expression of DNA replication genes</article-title><source>J Bone Miner Res</source><year>2004</year><volume>19</volume><fpage>133</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">14753745</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milos</surname><given-names>C</given-names></name><name><surname>Iqbal</surname><given-names>S</given-names></name><name><surname>Donald</surname><given-names>G</given-names></name></person-group><article-title>Combination treatment with progesterone and vitamin D hormone may be more effective than monotherapy for nervous system injury and disease</article-title><source>Neuroendocrinology</source><year>2009</year><volume>30</volume><fpage>158</fpage><lpage>72</lpage></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergeron</surname><given-names>R</given-names></name><name><surname>de Montigny</surname><given-names>C</given-names></name><name><surname>Debonnel</surname><given-names>G</given-names></name></person-group><article-title>Pregnancy reduces brain sigma receptor function</article-title><source>Br J Pharmacol</source><year>1999</year><volume>127</volume><fpage>1769</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">10482906</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanner</surname><given-names>M</given-names></name><name><surname>Moebius</surname><given-names>FF</given-names></name><name><surname>Flandorfer</surname><given-names>A</given-names></name><name><surname>Knaus</surname><given-names>HG</given-names></name><name><surname>Striessnig</surname><given-names>J</given-names></name><name><surname>Kempner</surname><given-names>E</given-names></name><etal/></person-group><article-title>Purification, molecular cloning, and expression of the mammalian sigma1-binding site</article-title><source>Proc Natl Acad Sci U S A</source><year>1996</year><volume>93</volume><fpage>8072</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">8755605</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valera</surname><given-names>S</given-names></name><name><surname>Ballivet</surname><given-names>M</given-names></name><name><surname>Bertrand</surname><given-names>D</given-names></name></person-group><article-title>Progesterone modulates a neuronal nicotinic acetylcholine receptor</article-title><source>Proc Natl Acad Sci U S A</source><year>1992</year><volume>89</volume><fpage>9949</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">1409725</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eelen</surname><given-names>G</given-names></name><name><surname>Verlinden</surname><given-names>L</given-names></name><name><surname>van Camp</surname><given-names>M</given-names></name><name><surname>van Hummelen</surname><given-names>P</given-names></name><name><surname>Marchal</surname><given-names>K</given-names></name><name><surname>de Moor</surname><given-names>B</given-names></name><etal/></person-group><article-title>The effects of 1alpha,25-dihydroxyvitamin D3 on the expression of DNA replication genes</article-title><source>J Bone Miner Res</source><year>2004</year><volume>19</volume><fpage>133</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">14753745</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cantorna</surname><given-names>MT</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Froicu</surname><given-names>M</given-names></name><name><surname>Wittke</surname><given-names>A</given-names></name></person-group><article-title>Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system</article-title><source>Am J Clin Nutr</source><year>2004</year><volume>80</volume><fpage>1717S</fpage><lpage>20S</lpage><pub-id pub-id-type="pmid">15585793</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christakos</surname><given-names>S</given-names></name><name><surname>Dhawan</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Peng</surname><given-names>X</given-names></name><name><surname>Porta</surname><given-names>A</given-names></name></person-group><article-title>New insights into the mechanisms of vitamin D action</article-title><source>J Cell Biochem</source><year>2003</year><volume>88</volume><fpage>695</fpage><lpage>705</lpage><pub-id pub-id-type="pmid">12577303</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen-Lahav</surname><given-names>M</given-names></name><name><surname>Douvdevani</surname><given-names>A</given-names></name><name><surname>Chaimovitz</surname><given-names>C</given-names></name><name><surname>Shany</surname><given-names>S</given-names></name></person-group><article-title>The anti-inflammatory activity of 1,25- dihydroxyvitamin D3 in macrophages</article-title><source>J Steroid Biochem Mol Biol</source><year>2007</year><volume>103</volume><fpage>558</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">17267205</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname><given-names>CL</given-names></name><name><surname>Gray</surname><given-names>LJ</given-names></name><name><surname>Bath</surname><given-names>PM</given-names></name><name><surname>Murphy</surname><given-names>SP</given-names></name></person-group><article-title>Progesterone for the treatment of experimental brain injury; a systematic review</article-title><source>Brain</source><year>2008</year><volume>131</volume><fpage>318</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">17715141</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>M</given-names></name><name><surname>Sumien</surname><given-names>N</given-names></name><name><surname>Kyser</surname><given-names>C</given-names></name><name><surname>Simpkins</surname><given-names>JW</given-names></name></person-group><article-title>Estrogens and progesterone as neuroprotectants: What animal models teach us</article-title><source>Front Biosci</source><year>2008</year><volume>13</volume><fpage>1083</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">17981614</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>DG</given-names></name></person-group><article-title>Progesterone exerts neuroprotective effects after brain injury</article-title><source>Brain Res Rev</source><year>2008</year><volume>57</volume><fpage>386</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">17826842</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cutler</surname><given-names>SM</given-names></name><name><surname>Cekic</surname><given-names>M</given-names></name><name><surname>Miller</surname><given-names>DM</given-names></name><name><surname>Wali</surname><given-names>B</given-names></name><name><surname>VanLandingham</surname><given-names>JW</given-names></name><name><surname>Stein</surname><given-names>DG</given-names></name></person-group><article-title>Progesterone improves acute recovery after traumatic brain injury in the aged rat</article-title><source>J Neurotrauma</source><year>2007</year><volume>24</volume><fpage>1475</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">17892409</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>J</given-names></name><name><surname>Hoffman</surname><given-names>SW</given-names></name><name><surname>Stein</surname><given-names>DG</given-names></name></person-group><article-title>Allopregnanolone, a progesterone metabolite, enhances behavioral recovery and decreases neuronal loss after traumatic brain injury</article-title><source>Restor Neurol Neurosci</source><year>2004</year><volume>22</volume><fpage>19</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">15096691</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Chiang</surname><given-names>YH</given-names></name><name><surname>Su</surname><given-names>TP</given-names></name><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Morales</surname><given-names>M</given-names></name><name><surname>Hoffer</surname><given-names>BJ</given-names></name><etal/></person-group><article-title>Vitamin D(3) attenuates cortical infarction induced by middle cerebral arterial ligation in rats</article-title><source>Neuropharmacology</source><year>2000</year><volume>39</volume><fpage>873</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">10699453</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Almeras</surname><given-names>L</given-names></name><name><surname>Eyles</surname><given-names>D</given-names></name><name><surname>Benech</surname><given-names>P</given-names></name><name><surname>Laffite</surname><given-names>D</given-names></name><name><surname>Villard</surname><given-names>C</given-names></name><name><surname>Patatian</surname><given-names>A</given-names></name><etal/></person-group><article-title>Developmental vitamin D deficiency alters brain protein expression in the adult rat: Implications for neuropsychiatric disorders</article-title><source>Proteomics</source><year>2007</year><volume>7</volume><fpage>769</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">17295352</pub-id></element-citation></ref></ref-list></back></article>